ShareValue scores for STVN: Valuation 45, Quality 49, Growth 35, Health 50.

Stevanato Group SpA logo

STVN
NYSE

Stevanato Group SpA

$20.29(+0.95%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 15%
Valuation
45
Fair Value
Price vs Value
Quality
49
Moderate
Business Strength
Growth
35
Weak
Revenue & Earnings
Health
50
Moderate
Financial Stability
Momentum
50
Neutral
Price Trend

Company Details

About

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026